Measles antibody in vaccinated human immunodeficiency virus type 1-infected children. 1996

S M Arpadi, and L E Markowitz, and A L Baughman, and K Shah, and H Adam, and A Wiznia, and G Lambert, and J Dobroszycki, and J L Heath, and W J Bellini
Bronx-Lebanon Hospital Center, USA.

OBJECTIVE The goals of this study were to evaluate the proportion of previously vaccinated human immunodeficiency virus (HIV) type 1-infected children with detectable postvaccination measles antibody; to assess risk factors for vaccine failure; and to evaluate the response to reimmunization. METHODS A total of 81 perinatally HIV-infected children receiving medical care in the Bronx, New York who had previously received measles vaccine were enrolled. The Centers for Disease Control and Prevention (CDC) HIV class, lymphocyte subsets, and measles antibody were determined upon enrollment. Additional data abstracted from medical records included dates and number of prior measles vaccinations and CDC HIV class at the time of vaccination. Measles antibody was determined by microneutralization enzyme-linked immunosorbent assay (ELISA). RESULTS The median age at time of study was 42 months (range, 9 to 168 months). Overall, 58 (72%) subjects had detectable measles antibody (microneutralization ELISA titer > 1:5). Children studied within 1 year of vaccination were more likely to have detectable measles antibody than children evaluated more than 1 year after vaccination (83% vs 52%, P < .01). The proportion of children with detectable measles antibody was higher among children with no or moderate immunosuppression compared to those with severe immunosuppression when immune status was based on CD4%. Children vaccinated at 6 to 11 months of age appeared to have a higher proportion of detectable measles antibody than those who received a first measles vaccination after age 1. Only 1 (14%) of 7 previously vaccinated children who were seronegative or had very low titers experienced a four-fold rise in measles antibody when reimmunized. CONCLUSIONS These results support current recommendations to vaccinate HIV-infected children against measles. The proportion of children with detectable measles antibody among vaccinated HIV-infected children is considerably lower than in vaccinated healthy children. HIV-infected children may respond better to measles vaccine when it is administered before the first birthday. From our limited data it appears that reimmunization of previously vaccinated HIV-infected children with moderate to severe immunosuppression does not result in an antibody recall response.

UI MeSH Term Description Entries
D007108 Immune Tolerance The specific failure of a normally responsive individual to make an immune response to a known antigen. It results from previous contact with the antigen by an immunologically immature individual (fetus or neonate) or by an adult exposed to extreme high-dose or low-dose antigen, or by exposure to radiation, antimetabolites, antilymphocytic serum, etc. Immunosuppression (Physiology),Immunosuppressions (Physiology),Tolerance, Immune
D007117 Immunization, Secondary Any immunization following a primary immunization and involving exposure to the same or a closely related antigen. Immunization, Booster,Revaccination,Secondary Immunization,Booster Immunization,Booster Immunizations,Immunizations, Booster,Immunizations, Secondary,Revaccinations,Secondary Immunizations
D007223 Infant A child between 1 and 23 months of age. Infants
D008458 Measles Vaccine A live attenuated virus vaccine of chick embryo origin, used for routine immunization of children and for immunization of adolescents and adults who have not had measles or been immunized with live measles vaccine and have no serum antibodies against measles. Children are usually immunized with measles-mumps-rubella combination vaccine. (From Dorland, 28th ed) Vaccine, Measles
D008459 Measles virus The type species of MORBILLIVIRUS and the cause of the highly infectious human disease MEASLES, which affects mostly children. Edmonston virus
D009500 Neutralization Tests The measurement of infection-blocking titer of ANTISERA by testing a series of dilutions for a given virus-antiserum interaction end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (CPE) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50). Neutralization Test,Test, Neutralization,Tests, Neutralization
D009519 New York City City located at the mouth of the Hudson River, in New York State.
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked

Related Publications

S M Arpadi, and L E Markowitz, and A L Baughman, and K Shah, and H Adam, and A Wiznia, and G Lambert, and J Dobroszycki, and J L Heath, and W J Bellini
February 1995, The Pediatric infectious disease journal,
S M Arpadi, and L E Markowitz, and A L Baughman, and K Shah, and H Adam, and A Wiznia, and G Lambert, and J Dobroszycki, and J L Heath, and W J Bellini
December 2007, The Journal of infectious diseases,
S M Arpadi, and L E Markowitz, and A L Baughman, and K Shah, and H Adam, and A Wiznia, and G Lambert, and J Dobroszycki, and J L Heath, and W J Bellini
May 1989, JAMA,
S M Arpadi, and L E Markowitz, and A L Baughman, and K Shah, and H Adam, and A Wiznia, and G Lambert, and J Dobroszycki, and J L Heath, and W J Bellini
December 1995, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association,
S M Arpadi, and L E Markowitz, and A L Baughman, and K Shah, and H Adam, and A Wiznia, and G Lambert, and J Dobroszycki, and J L Heath, and W J Bellini
August 1994, The Pediatric infectious disease journal,
S M Arpadi, and L E Markowitz, and A L Baughman, and K Shah, and H Adam, and A Wiznia, and G Lambert, and J Dobroszycki, and J L Heath, and W J Bellini
April 1996, The Pediatric infectious disease journal,
S M Arpadi, and L E Markowitz, and A L Baughman, and K Shah, and H Adam, and A Wiznia, and G Lambert, and J Dobroszycki, and J L Heath, and W J Bellini
July 1998, The Pediatric infectious disease journal,
S M Arpadi, and L E Markowitz, and A L Baughman, and K Shah, and H Adam, and A Wiznia, and G Lambert, and J Dobroszycki, and J L Heath, and W J Bellini
December 1997, The Pediatric infectious disease journal,
S M Arpadi, and L E Markowitz, and A L Baughman, and K Shah, and H Adam, and A Wiznia, and G Lambert, and J Dobroszycki, and J L Heath, and W J Bellini
July 1994, The Journal of pediatrics,
S M Arpadi, and L E Markowitz, and A L Baughman, and K Shah, and H Adam, and A Wiznia, and G Lambert, and J Dobroszycki, and J L Heath, and W J Bellini
December 1992, The Pediatric infectious disease journal,
Copied contents to your clipboard!